Sung-Ick Park

Title: Innovations of Sung-Ick Park in Inhalable Powder Formulations

Introduction

Sung-Ick Park is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of inhalable powder formulations. His work focuses on addressing NMDA receptor hypofunction-related diseases, which are critical in various neurological conditions.

Latest Patents

Sung-Ick Park holds a patent for the "Use of inhalable powder formulation comprising growth hormone for preventing or treating NMDA receptor hypofunction-related diseases." This patent describes a method for administering a therapeutically effective amount of an inhalable powder formulation containing growth hormone (GH) to treat or prevent NMDA receptor hypofunction-related diseases. The formulation aims to provide a novel approach to managing these conditions effectively.

Career Highlights

Sung-Ick Park is associated with Medigenebio Corporation, where he continues to innovate in the field of inhalable drug delivery systems. His expertise in pharmaceutical sciences has positioned him as a key player in developing new therapeutic strategies.

Collaborations

Sung-Ick Park collaborates with Sy Lee, contributing to advancements in their shared field of research. Their partnership enhances the potential for innovative solutions in treating complex diseases.

Conclusion

Sung-Ick Park's work exemplifies the intersection of innovation and healthcare, particularly through his patented formulations aimed at treating NMDA receptor hypofunction-related diseases. His contributions are paving the way for new therapeutic options in the pharmaceutical industry.